Cannabinoids, endogenous ligands and synthetic analogs

Current Opinion in Chemical Biology

Volumn 3, Issue 4, 1999, Pages 418-425

  Pop, Emil ^a  

^a Alchem Laboratories Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; AJULEMIC ACID; ANANDAMIDE; CANNABIDIOL; CANNABINOID; CANNABINOID DERIVATIVE; CANNABINOL; CANNABIS; DEXANABINOL; DRONABINOL; GLYCEROL DERIVATIVE; LIGAND; NABILONE; RIMONABANT; UNCLASSIFIED DRUG;

DRUG BINDING; DRUG SYNTHESIS; LIGAND BINDING; REVIEW;

CANNABIS;

EID: 0033178909     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(99)80062-3     Document Type: Article

References (56)

1. Pertwee RG: Pharmacological physiological and clinical implications of the discovery of cannabinoid receptors. Biochem Soc Trans 1998, 26:267-272. Modalities to modulate levels of endocannabinoids by inhibiting anandamine hydrolysis are reviewed. Various inhibitors of fatty acid amide hydrolase, which could activate the endogenous cannabinoid system, are reviewed.
2. Felder CC, Glass M: Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol 1998, 38:179-200.
3. Klein TW, Newton C, Friedman H: Cannabinoid receptors and immunity. Immunol Today 1998, 19:373-381. Evidence suggest that a CBR-ligand system exists in the immune system and has some role in immune homeostasis and that cannabinoids modulate immunity. The review also emphasizes that the function and distribution of receptor subtypes in various immune compartments, and many other basic issues, still need clarification.
4. Pettit DA, Harrison MP, Olson JM, Spencer RF, Cabral GA: Immunohistochemical localization of the neural cannabinoid receptor in rat brain. J Neurosci Res 1998, 51:391-402.
5. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM: Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998, 83:393-411.
6. McIntosh HH, Song C, Howlet AC: CB1 cannabinoid receptor: Cellular regulation and distribution in N18TG2 neuroblasma cells. Brain Res Mol Brain Res 1998, 53:163-173.
7. Romero J, de Miguel R, Ramos JA, Fernandez-Ruiz JJ: The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake. Life Sci 1998, 62:351-363.
8. Garcia DE, Brown S, Hille B, Mackie K: Protein kinase C disrupts cannabinoid actions by phosphorylation of the CB1 cannabinoid receptor. J Neurosci 1998, 18:2834-2841.
9. Marmor JB: Medical marijuana. West J Med 1998, 168:540-543.
10. Crites-Leoni A: Medicinal use of marijuana. J Leg Med 1998, 19:273-304.
11. Abrams DI: Medical marijuana: Tribulations and trials. J Psychoactive Drugs 1998, 30:187-196.
12. Grotenhermen F: Therapeutic use of cannabis [letter to editor]. Lancet 1998, 351:758-759.
13. Court JM: Cannabis and brain function. J Pediatr Child Health 1998, 34:1-5.
14. Klein TW, Friedman H, Specter S: Marijuana, immunity and infection. J Neuroimmunol 1998, 83:102-115.
15. Cabral GA, Dove Pettit DA: Drugs and immunity: Cannabinoids and their role in decreased resistance to infectious disease. J Neuroimmunol 1998, 83:116-123.
16. 9-tetrehydrocannabinol. J Neurosci 1998, 18:5322-5332.
17. Gessa GL, Melis M, Muntoni AL, Diana M: Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 1998, 341:39-44.
18. 9-tetrahydrocannabinol. Pharmacol Biochem Behav 1998, 60:559-566.
19. 9 tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998, 95:8268-8273. The antioxidant capacity, proven by cyclic voltametry and in a chemical (Fenton reaction) system for THC and cannabidiol (and earlier for the nonpsychotropic synthetic cannabinoid HU-211) appears to be a common property of classical cannabinoid structures. Obviously, the phenol is responsible for this property. The potential use of nontoxic cannabidiol as a neuroprotective agent (e.g. in ischemic stroke) is of particular interest.
20. Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC: Complex pharmacology of natural cannabinoids: Evidence for partial agonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 1998, 63:PL1-6. THC does not induce the maximal effect obtained by classical CBR agonists such as 8; in fact, at high concentrations, THC exhibits antagonistic properties. Cannabinol is a weak agonist and cannabidiol is an antagonist acting in the micromolar range. The variable ratio of THC, cannabinol and cannabidiol in marijuana might influence its pharmacological effects.
21. Levenes C, Daniel H, Soubrie P, Crepel F: Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells. J Physiol (Lond) 1998, 510:867-879.
22. Colombo G, Agabio R, Lobina C, Reali R, Gessa GL: Cannabinoid modulation of intestinal propulsion in mice. Eur J Pharmacol 1998, 344:67-69.
23. Carriero D, Aberman J, Lin SY, Hill A, Makriynnis A, Salamone JD: A detailed characterization of the effects of four cannabinoid agonists on operant lever pressing. Psychopharmacology (Berl) 1998, 137:147-156.
24. Shen M, Thayer SA: Cannabinoid receptor agonists protect cultured hippocampal neurons from excitotoxicity. Mol Pharmacol 1998, 54:459-462.
25. 8-tetrahydrocannabinol and its active metabolites for cannabinoid receptor binding. Biol Pharm Bull 1998, 21:408-410.
26. MacLennan SJ, Reynen PH, Kwan J, Bonhaus DW: Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br J Pharmacol 1998, 124:619-622.
27. Vivian JA, Kishioka S, Butelman ER, Broadbear J, Lee KO, Woods JH: Analgesic, respiratory and heart rate effects of cannabinoids and opioid antagonists in rhesus monkey: Antagonist effects of SR 14176A. J Pharmacol Exp Ther 1998, 286:697-703. THC and WIN 55212 dose-dependently increased antinociception and decreased respiratory minute and tidal volumes and heart rate in 12 adult rhesus monkies. These effects, also induced by anandamide, were selectively reversed by SR 14176A.
28. 8-THC-11-oic acid (CT3) in mice. Life Sci 1998, 63:161-168. New data characterizing the analgesic properties of the nontoxic CT3, administered in various ways, in several animal assays are presented.
29. Zurier RB, Rosetti RG, Lane JH, Goldberg JM, Hunter SA, Burstein SH: Dimethylheptyl-THC-oic acid: A nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum 1998, 41:163-170. Suppression of acute inflammation in the subcutaneous air pouch in mice and chronic joint inflammation characteristic of adjuvant disease in rats demonstrated dimethylheptyl-THC-oic acid's potential use as an anti-inflammatory agent.
30. 8-tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats. Eur J Pharmacol 1998, 344:77-86.
31. Drake DJ, Jensen RS, Busch-Petersen J, Kawakami JK, Conception Fernandez-Garcia M, Fan P, Makriyannis A, Tius MA: Classical/nonclassical hybrid cannabinoids: Southern aliphatic chain-functionalized C-6β-methyl, ethyl and propyl analogues. J Med Chem 1998, 41:3596-3608. The influence of a southern aliphatic hydroxyl (SAH) pharmacophore was studied through varying the chain length of the SAH moiety and by analysing the effects of replacing the hydroxyl functionality with hydrogen and iodide; results indicated that the SAH pharmacophore has less pronounced effects than the C3 aliphatic chain.
32. Xie XQ, PavlopouloS S, DiMeglio CM, Makriyannis A: Conformational studies on a diastereoisomeric pair of tricyclic nonclassical cannabinoids by NMR spectroscopy and computer molecular modeling. J Med Chem 1998, 41:167-174.
33. Papahatjis DP, Kourouli T, Abadji V, Goutopoulos A, Makriyannis A: Pharmacophoric requirements for cannabinoid side chains: Multiple bond and C1′-substituted Δ8-tetrahydrocannabinols. J Med Chem 1998, 41:1195-1200.
34. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B et al.: SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 1998, 284:644-650.
35. Thomas BF, Gilliam AF, Burch DF, Roche MJ, Selzman HH: Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 1998, 285:285-292.
36. Felder CC, Joyce KE, Briley EM, Glass M, Mackie KP, Fahey KJ, Cullinan GJ, Hunden DC, Johnson DW, Chaney MO et al.: LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther 1998, 284:291-297.
37. Wiley JL, Compton DR, Dai D, Lainton JA, Philips M, Huffman JW, Martin BR: Structure-activity relationship of indole- and pyrrole-derived cannabinoids. J Pharmacol Exp Ther 1998, 285:995-1004.
38. Di Marzo V: Endocannabinoids and other fatty acid derivatives with cannabimimetic properties: Biochemistry and possible physiopathological relevance. Biochim Biophys Acta 1998, 1392:153-175. This is a comprehensive review of the metabolic pathways (formation and inactivation) and the molecular mode of actions of endocannabinoids.
39. Goparaju SK, Ueda N, Yamaguchi H, Yamamoto S: Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett 1998, 422:69-73.
40. Di Marzo V, Bisogno T, Sugiura T, Melck D, De Petrocellis L: The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: Connection with anandamide. Biochem J 1998, 331:15-19.
41. Ben-Shabat S, Fride E, Sheshkin T, Tamiri T, Rhee M-H, Vogel Z, Bisogno T, De Petrocellis L, Di Marzo V, Mechoulam R: An entourage effect: Inactive endogenous fatty acid glyceryl esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 1998, 353:23-31.
42. Molina-Holgado F, Molina-Holgado E, Guaza C: The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett 1998, 433:139-142.
43. Hampson AJ, Bornheim LM, Scaniziani M, Yost CVS, Gray AT, Hansen BM, Leonoudakis DJ, Bickler PE: Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J Neurochem 1998, 70:671-676.
44. Adams IB, Compton DR, Martin BR: Assessment of anandamide interaction with the cannabinoid receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 1998, 284:1209-1217.
45. Patel NA, Moldow RL, Patel JA, Wu G, Chang SL: Arachidonylethanolamide (AEA) activation of FOS proto-oncogene protein immunoreactivity in the rat brain. Brain Res 1998, 797:225-233.
46. Sulcova E, Mechoulam R, Fride E: Biphasic effects of anandamide. Pharmacol Biochem Behav 1998, 59:347-352.
47. Randall MD, Kendal DA: Endocannabinoids: A new class of vasoactive substances. Trends Pharmacol Sci 1998, 19:55-58.
48. Mechoulam R, Fride E, Ben-Shabat S, Meiri U, Horowitz M: Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid. Eur J Pharmacol 1998, 362:R1-R3.
49. Sugiura T, Kodaka T, Nakane S, Kishimoto S, Kondo S, Waku K: Detection of an endogenous cannabimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: Is 2-arachidonoylglycerol a possible vasomodulator? Biochem Biophys Res Commun 1998, 243:838-843.
50. Pratt PF, Hillard CJ, Edgemond WS, Campbell WB: N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1. Am J Physiol 1998, 274:375-381.
51. De PetroceLLis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M, Di Marzo V: The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA 1998, 95:8375-8380. AEA proved to be a potent and selective inhibitor of the proliferation of human breast cancer; activation of a CBR, the occurrence of which has never been described previously in these cells, is at least partially responsible for this effect.
52. Bisogno T, Katayama K, Melck D, Ueda N, De Petrocellis L, Yamamoto S, Di Marzo V: Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells - Implications for cell proliferation and differentiation. Eur J Biochem 1998, 254:634-642. In vitro studies demonstrated that non-nervous tumoral cells have the means to both synthesize and inactivate AEA and the sleep-inducing factor oleamide, which may function as autocrine, protective signals for the down-regulation of human breast cancer proliferation.
53. Calignano A, La Rana G, Giuffrida A, Piomelli D: Control of pain initiation by endogenous cannabinoids. Nature 1998, 394:277-281. Palmytylethanolamide (PEA) (23) exerts similar effects (i.e. control of pain initiation) by activating peripheral CB2-like receptors. Administered together, AEA and PEA act synergistically, reducing pain responses 100-fold more potently than each compound alone. Since 10 (a CB1 antagonist) and 16 (a CB2 antagonist) prolong and enhance the pain behavior, it is obvious that peripheral CB-like receptors participate in the intrinsic control of pain initiation and that locally generated AEA and PEA may mediate this effect.
54. Di Marzo V, Sepe N, De Petrocellis L, Berger A, Crazier G, Friede E, Mechoulam R: Trick or treat from food endocannabinoids? Nature 1998, 396:636-637.
55. Edgemond WS, Greenberg MJ, McGinley PJ, Muthian S, Campbell WB, Hillard CJ: Synthesis and characterization of diazomethylarachidonyl ketone: An irreversible inhibitor of N-arachidonylethanolamine aminohydrolase. J Pharmacol Exp Ther 1998, 286:184-190.
56. Edgemond WS, Hillard CJ, Falck JR, Kearn CS, Campbell WB: Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): Their affinities for cannabinoid receptors and pathways of inactivation. Mol Pharmacol 1998, 54:180-188.